Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.
Spanish pharmaceutical company best known for the antihistamine bilastine, also making generics and animal-health products.
Licenses bilastine to pharmaceutical partners in many countries, who sell it under their own brands, while Faes earns by supplying the active ingredient and from licence payments. A separate business sells prescription and generic medicines in Spain through pharmacies and hospitals.
In one line: A smaller, diversified generics/specialty pharma.
Moat: narrow (IP / patents, distribution). Bilastine licensing income is a durable niche, but broader portfolio faces generic competition.
Headquarters: Bilbao, Spain · Founded: 1933
Size Faes Farma (FAE.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $1.71B, the 57th largest of 93 Spain companies the cockpit tracks. Shares closed at €4.99 on 18 Nov 2026.
Performance Over six months the shares gained 6.0%, against +1.7% for the median peer and +5.3% for the Spain market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 31.9% over the last twelve months (peer median +6.8%); the operating margin is 14.1% (peer median 8.6%).
Valuation It trades at 17.4× forward earnings against a peer median of 21.0× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.4 points above its cost of capital (5.7% WACC).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €697M | €610M | €494M | €451M | €439M |
| Revenue growth | — | +24% | +9% | +3% | — |
| Gross profit | €259M | €228M | €201M | €181M | €172M |
| EBITDA | €136M | €102M | €113M | €101M | €98.6M |
| Net income | €84.2M | €79.6M | €111M | €91.9M | €89.5M |
| Free cash flow | €61.6M | €62.4M | €81.7M | €5.21M | €31.8M |
| Capital expenditure | €25.6M | €23.6M | €39.6M | €102M | €80.9M |
| Total debt | n/a | €410M | €7.79M | €8.23M | €7.61M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Faes Farma FAE.MC | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% |
| Almirall ALM.MC | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FAE.MC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.9% | -1.4% | 7th highest of 21 |
| 6-month return | +6.0% | +1.7% | 6th highest of 20 |
| Distance from 52-week high | -8.4% | -35.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +31.9% | +6.8% | 5th highest of 20 |
| Operating margin | 14.1% | 8.6% | 8th highest of 20 |
| Forward P/E | 17.4× | 21.0× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 3.7% | 18.4% | 6th least demanding of 16 |
| Growth delivered (Del g) | +9.9% | +9.2% | 8th highest of 16 |
| Hurdle (Req g minus delivered) | -6.2 pp | +2.0 pp | 6th least demanding of 16 |
| ROIC minus cost of capital | +1.4 pp | -2.7 pp | 9th highest of 21 |
| EV / EBITDA | 13.4× | 21.5× | 3rd cheapest of 9 |
| Net debt / EBITDA | 1.9× | -1.4× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Faes Farma FAE.MC | Spain | $1.71B | +6% | +32% | 14% | 17.4× | 3.7% | +9.9% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |
| ApicHope Pharmaceutical 300723.SZ | China | $1.70B | -36% | -28% | -50% | 22.0× | 11.3% | -11.0% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.70B | +2% | +17% | 31% | 21.4× | 24.3% | +15.7% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Mayinglong Pharmaceutical 600993.SS | China | $1.70B | +2% | +7% | 17% | 17.0× | -3.5% | +6.8% |
| Indegene INDGN.NS | India | $1.69B | +28% | +36% | 12% | 29.5× | 31.4% | +29.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.67B | -12% | +7% | 39% | 26.3× | 18.4% | +10.8% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +8% | +15% | 35% | 9.2× | -14.9% | +13.5% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Shenzhen Hepalink Pharmaceutical 9989.HK | Hong Kong | $1.78B | -13% | -1% | 8% | 8.7× | -0.4% | -0.2% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $1.62B | -47% | -18% | 9% | n/a | 33.0% | +0.9% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.62B | -30% | +30% | 10% | n/a | 42.4% | +23.0% |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |